13,309 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Quadrature Capital Ltd

Quadrature Capital Ltd bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,309 shares of the medical research company’s stock, valued at approximately $3,365,000.

A number of other hedge funds have also recently bought and sold shares of the company. AdvisorNet Financial Inc raised its stake in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after purchasing an additional 95 shares during the period. Rise Advisors LLC purchased a new position in shares of IQVIA in the 1st quarter valued at $31,000. Riverview Trust Co purchased a new position in shares of IQVIA in the 1st quarter valued at $32,000. Activest Wealth Management purchased a new position in shares of IQVIA in the 4th quarter valued at $35,000. Finally, Covestor Ltd raised its stake in shares of IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 48 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research reports. Evercore ISI raised their target price on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Truist Financial raised their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. The Goldman Sachs Group assumed coverage on shares of IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price on the stock. Finally, Robert W. Baird raised their price target on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $263.56.

IQVIA Stock Up 3.2 %

IQV stock traded up $7.38 during mid-day trading on Friday, hitting $239.67. 1,195,238 shares of the company were exchanged, compared to its average volume of 1,420,984. The company has a market capitalization of $43.69 billion, a PE ratio of 32.74, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.88 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The firm has a fifty day simple moving average of $220.23 and a 200 day simple moving average of $229.46.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same period in the previous year, the business posted $2.22 EPS. The company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.21 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.